Effects of fluconazole on the pharmacokinetics and pharmacodynamics of antimony in cutaneous leishmaniasis-infected hamsters

International Journal of Antimicrobial Agents

Volumn 29, Issue 6, 2007, Pages 728-732

  Alnaim, Lamya ^a   Abou Alsoud, Nermeen ^a   Zaghloul, Iman ^a   AL Jaser, May ^b  

^a Science and Medical Studies Department for Women Students   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antimony; Fluconazole; Leishmaniasis; Pharmacokinetics; Sodium stibogluconate

Indexed keywords

ANTIMONY; FLUCONAZOLE; STIBOGLUCONATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; FOOT PAD; HAMSTER; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; ANTIMONY; ANTIPROTOZOAL AGENTS; AREA UNDER CURVE; CRICETINAE; DRUG THERAPY, COMBINATION; FLUCONAZOLE; HALF-LIFE; INJECTIONS, INTRAVENOUS; LEISHMANIASIS, CUTANEOUS; MESOCRICETUS; RANDOM ALLOCATION;

EID: 34248230218     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.01.013     Document Type: Article

References (18)

1. World Health Organization. Control of the leishmaniases. Technical report series no. 793. Geneva, Switzerland: WHO; 1990.
2. Davies C.R., Kaye P., Croft S.L., and Sundar S. Leishmaniasis: new approaches to disease control. BMJ 326 (2003) 377-382
3. Moskowitz P.F., and Kurban A.K. Treatment of cutaneous leishmaniasis: retrospectives and advances for the 21st century. Clin Dermatol 17 (1999) 305-315
4. Hepburn N.C. Management of cutaneous leishmaniasis. Curr Opin Infect Dis 14 (2001) 151-154
5. Arevalo I., Ward B., Miller R., et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 33 (2001) 1847-1851
6. Momeni A.Z., Jalayer T., Emamjomeh M., et al. Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blinded study. Arch Dermatol 132 (1996) 784-786
7. Pirson P., Leclef B., and Trouet A. Activity of ketoconazole derivatives against Leishmania mexicana amazonensis within mouse peritoneal macrophages. Ann Trop Med Parasitol 84 (1990) 133-139
8. Alrajhi A.A., Ibrahim E.A., De Vol E.B., Khairat M., Faris R.M., and Maguire J.H. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346 (2002) 891-895
9. Veiga J.P., Wolff E.R., Sampaio R.N., and Marsden P.D. Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials. Lancet ii (1983) 569
10. Gibaldi M., and Perrier D. Pharmacokinetics. 2nd ed. (1982), Marcel Dekker, New York
11. Berman J.D., Gallalee J.F., and Gallalee J.V. Pharmacokinetics of pentavalent antimony (Pentostam) in hamsters. Am J Trop Med Hyg 39 (1988) 41-45
12. AL-Jaser M., el-Yazigi A., Kojan M., and Croft S.L. Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. Antimicrob Agents Chemother 39 (1995) 516-519
13. AL-Jaser M., el-Yazigi A., and Croft S.L. Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharm Res 12 (1995) 113-116
14. Belloli C., Crescenzo G., Carli S., et al. Disposition of antimony and aminosidine combination after multiple subcutaneous injections in dogs. Vet J 157 (1999) 315-321
15. Chulay J.D., Fleckenstein L., and Smith D.H. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg 82 (1988) 69-72
16. Zaghloul I.Y., and AL-Jaser M. Effect of renal impairment on the pharmacokinetics of antimony in hamsters. Ann Trop Med Parasitol 98 (2004) 793-800
17. Al-Abdely H.M., Graybill J.R., Bocanegra R., et al. Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis. Antimicrob Agents Chemother 42 (1998) 2542-2548
18. Zvulunov A., Klaus S., and Vardy D. Fluconazole for the treatment of cutaneous leishmaniasis. N Engl J Med 347 (2002) 370-371